PHP
LEGN icon

Parkman Healthcare Partners’s Legend Biotech LEGN Stock Holding History

Parkman Healthcare Partners’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-47,608
Closed -$2.3M – 100
2023
Q1 		$2.3M Sell
47,608
-44,324
-48% -$2.17M 0.5% 54
2022
Q4 		$4.59M Sell
91,932
-29,295
-24% -$1.42M 1.22% 33
2022
Q3 		$4.95M Buy
121,227
+3,420
+3% +$161K 1.41% 22
2022
Q2 		$6.48M Sell
117,807
-2,666
-2% -$113K 2.39% 14
2022
Q1 		$4.38M Buy
+120,473
New +$4.76M 1.28% 30

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Parkman Healthcare Partners's LEGN Position: Q2 2023 in Review

Parkman Healthcare Partners sold out of Legend Biotech (LEGN) in Q2 2023, closing a stake of 47,608 shares — an estimated $2.3M sold.

Parkman Healthcare Partners first reported a position in LEGN in Q1 2022 and held it in 5 quarters. The position peaked at $6.48M in Q2 2022. 194 funds tracked by Wall St. Rank hold LEGN as of Q2 2023.

  • Parkman Healthcare Partners reported no remaining Legend Biotech position as of Q2 2023 after selling out during the quarter.
  • Parkman Healthcare Partners sold 47,608 Legend Biotech shares in Q2 2023, an estimated $2.3M.
  • Parkman Healthcare Partners first reported a position in Legend Biotech in Q1 2022 and held it in 5 quarters.
  • Parkman Healthcare Partners's Legend Biotech position peaked at $6.48M in Q2 2022.
  • 194 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2023.

Based on Parkman Healthcare Partners's 13F filing for Q2 2023, filed 11 Aug 2023.